Expand ALLR Menu
ALLR MENU

ALLR Latest Press Releases

-- May 15, 2026 --

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers Globe Newswire 4:30 PM

-- May 8, 2026 --

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm Globe Newswire 8:45 AM

-- May 5, 2026 --

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign Globe Newswire 8:00 AM

-- April 27, 2026 --

Allarity Therapeutics Announces that the Stenoparib DRP Test Has Received a Notice of Allowance from the US Patent and Trademark Office Globe Newswire 8:00 AM

-- April 21, 2026 --

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer Globe Newswire 8:00 AM

-- March 31, 2026 --

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress Globe Newswire 8:00 AM

-- March 6, 2026 --

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization Globe Newswire 8:00 AM

-- February 18, 2026 --

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need Globe Newswire 8:15 AM

-- February 3, 2026 --

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes